Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 Sales Top Estimates
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations, with sales up 15.7% year on year to $2.91 billion. The company expects the full year’s revenue to be around $11.
Vertex Pharmaceuticals Incorporated VRTX will report fourth-quarter and full-year 2024 earnings result on Feb. 10, after market close. The Zacks Consensus Estimate for sales and earnings for the ...
In this article we are going to estimate the intrinsic value of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by taking the expected future cash flows and discounting them to their present value.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback